Document is current
Any future updates will be listed below
-
Authors
Roberts, Kade D.
Zhu, Yan https://orcid.org/0000-0001-7342-3782
Azad, Mohammad A. K.
Han, Mei-Ling https://orcid.org/0000-0002-0861-2437
Wang, Jiping
Wang, Lynn
Yu, Heidi H. https://orcid.org/0000-0002-3337-1399
Horne, Andrew S.
Pinson, Jo-Anne https://orcid.org/0000-0001-6654-0278
Rudd, David
Voelcker, Nicolas H. https://orcid.org/0000-0002-1536-7804
Patil, Nitin A. https://orcid.org/0000-0003-0422-9411
Zhao, Jinxin
Jiang, Xukai
Lu, Jing https://orcid.org/0000-0002-5834-7942
Chen, Ke
Lomovskaya, Olga
Hecker, Scott J.
Thompson, Philip E. https://orcid.org/0000-0002-5910-7625
Nation, Roger L.
Dudley, Michael N.
Griffith, David C.
Velkov, Tony https://orcid.org/0000-0002-0017-7952
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI098771, R01AI132154)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
- License Information
-
More Information
Article History
Received: 23 October 2021
Accepted: 7 March 2022
First Online: 25 March 2022
Competing interests
: J.Li., T.V., R.L.N., K.D.R., P.E.T. are listed as inventors on the patent application WO2015149131 ‘Polymyxin Derivatives as Antimicrobial Compounds’ which covers F365 and the other lipopeptides listed in this manuscript and has been licensed to Qpex Biopharma. O.L., S.J.H., D.C.G., and M.N.D are employees of Qpex Biopharma and hold equity in that company. All other authors declare no competing interests.
